CEM Signs Exclusive Licensing Agreement with SpheriTech

News   Feb 28, 2014

 
CEM Signs Exclusive Licensing Agreement with SpheriTech
 
 
 

RELATED ARTICLES

Large Accumulation of ALS Protein Fibrils Not Toxic

News

Scientists have made a significant advance in the understanding of the complex and fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

READ MORE

PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.

READ MORE

Anti-Malaria Drugs Delivered With Caffeine

News

Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE